AI assistant
OptimizeRx Corp — Director's Dealing 2024
Jun 12, 2024
33090_dirs_2024-06-12_04217ef2-20fa-460e-b3b6-e3393be53081.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2024-04-18
Reporting Person: FEBBO WILLIAM J (Director, CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-18 | Common Stock | M | 28895 | — | Acquired | 582035 | Direct |
| 2024-04-18 | Common Stock | F | 782 | $9.35 | Disposed | 581253 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-04-18 | Restricted Stock Units | $ | M | 28895 | Disposed | Common (28895) | Direct |
Footnotes
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: The Reporting Person's prior holdings were previously inadvertently overstated by four shares.
F3: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended.
F4: On April 18, 2023, the Reporting Person was granted 86,685 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.